Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases [6] - The company has entered into an exclusive distribution agreement for ProIBS® in Australia and New Zealand, expanding its product portfolio [1][4] Product Information - ProIBS® is a certified medical device designed to treat symptoms of irritable bowel syndrome (IBS), including abdominal pain, bloating, and bowel movement issues [3] - The product contains AVH200®, derived from Aloe barbadensis Miller, which supports the intestinal mucosal barrier and is suitable for long-term use [3] - A usability study indicated that 94% of users found ProIBS® helpful, with 91% reporting an improvement in daily life and 98% willing to recommend it [3] Market Context - IBS affects approximately 30% of the population, with females being more likely to be affected [2] - The IBS treatment market in Australia is part of the broader "Digestives & Intestinal Remedies" market, projected to generate around AU$221.14 million in 2025, with an annual growth rate of 3.28% [2] Strategic Insights - The Chief Commercial Officer of Immuron highlighted the opportunity to expand the digestive health portfolio with ProIBS®, leveraging the success of the Travelan® brand [4] - The CEO of Calmino group AB expressed confidence in the collaboration with Immuron, recognizing Australia and New Zealand as significant markets with growth potential [5]

Core Insights - Immuron Limited has entered a research collaboration with Monash University to develop new therapeutic drug candidates targeting antimicrobial resistant pathogens [1][2] - The collaboration will utilize Immuron's technology platform and the expertise of the Biomedicine Discovery Institute led by Professor Dena Lyras [2] - The initial activities of the collaboration will not require additional funding beyond Immuron's existing research budget [3] Project Proposals - The first project will investigate the mechanisms by which bacteria share and transfer DNA, contributing to antimicrobial resistance, with the goal of developing broad-spectrum therapeutic products [5] - The second project will focus on Vancomycin-resistant enterococci (VRE), which are significant nosocomial pathogens that complicate treatment outcomes for vulnerable patients [7] Market Context - Antimicrobial resistance (AMR) is a major global health threat, leading to severe infections and increased healthcare costs, with the U.S. alone spending over $4.6 billion annually to treat such infections [6] - The global antibiotics market is projected to reach $57.0 billion by 2026, growing at a compound annual growth rate (CAGR) of 4.0%, driven by the rising prevalence of drug-resistant infections [8]

Core Insights - Immuron Limited has submitted the Clinical Study Report for its Phase 2 study of Travelan (IMM-124E) to the FDA and plans to request an end of Phase 2 meeting, which is necessary to advance to Phase 3 [1] Group 1: Clinical Study Results - The Phase 2 clinical study demonstrated statistically significant lower levels of IgA and IgG in subjects receiving Travelan compared to the placebo group, indicating reduced exposure to ETEC antigens [2] - There was a statistically significant reduction in the number of colony-forming units (CFUs) in the stools of subjects who received Travelan, measured 48 hours post-challenge (p = 0.0121), suggesting faster clearance of ETEC from the gastrointestinal tract [3] - Participants in the Travelan group exhibited a more stable gastrointestinal microbiota compared to the placebo group, with improved alpha diversity metrics indicating greater richness and evenness of bacterial species [4] Group 2: Microbiome Analysis - Statistically significant differences in beta diversity were observed between the treatment groups, with the Travelan group showing increased levels of beneficial bacteria such as Akkermansia and Faecalibacterium [5] - The data indicated a potential link between the presence of certain bacterial species and reduced inflammation, suggesting that Travelan may aid in the recovery of the gut microbiome [6] Group 3: Ongoing Studies - A field study conducted by the Uniformed Services University has randomized a total of 776 subjects to evaluate a dietary supplement for maintaining gut health during deployment and travel, with follow-up expected to be completed around June 2025 [7]

Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [4] - The company is listed on both the ASX (ASX: IMC) and NASDAQ (NASDAQ: IMRN) [4] Recent Company Highlights - Global sales increased by 172% in FY24, reaching $4.90 million, with record Travelan® sales of $4.86 million [4] - The company achieved record monthly sales of A$1.49 million in October 2024 (unaudited) [4] - Immuron is planning a Phase 2 trial for IMM-529 after receiving positive FDA pre-IND feedback [4] Product Information - Travelan® is an orally administered passive immunotherapy that reduces the likelihood of contracting travelers' diarrhea, caused by pathogenic bacteria [5] - Travelan® is a highly purified tabletized preparation of hyperimmune bovine antibodies, effective in binding to diarrhea-causing bacteria [5] - In Australia, Travelan® is listed as a medicine for reducing the risk of travelers' diarrhea and minor gastrointestinal disorders [5] Clinical Development - IMM-124E, the active ingredient in Travelan®, is developed from the colostrum of immunized cattle and targets enterotoxigenic E. coli (ETEC) [9][10] - IMM-529 is being developed as an adjunctive therapy for recurrent Clostridioides difficile infection (CDI), targeting multiple virulence components [13][14] - Pre-clinical results for IMM-529 show promising outcomes in preventing primary disease (80% efficacy), protecting against disease recurrence (67% efficacy), and treating primary disease (78.6% efficacy) [15]

Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [4] - The company is listed on both the Australian Securities Exchange (ASX: IMC) and NASDAQ (NASDAQ: IMRN) [4] Recent Developments - The Chief Executive Officer, Steven Lydeamore, presented at the 21st Virtual Investor Summit Microcap Event on November 21, 2024 [1] - A copy of the presentation is available on the company's website [2] Product Information - Travelan® is an orally administered passive immunotherapy that reduces the likelihood of contracting travelers' diarrhea, which is caused by pathogenic bacteria [5] - Travelan® is a highly purified tabletized preparation of hyperimmune bovine antibodies and is indicated for reducing the risk of travelers' diarrhea and minor gastrointestinal disorders in Australia and Canada [5] - In the U.S., Travelan® is marketed as a dietary supplement for digestive tract protection [5] Technology Platform - Immuron's proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum, allowing for the production of highly specific immunoglobulins to any enteric pathogen [7] - The platform technology enables the development of medicines across a wide range of infectious diseases by blocking viruses or bacteria at mucosal surfaces [7] Research and Development - IMM-124E, developed using Immuron's platform technology, is produced from the colostrum of immunized cattle and targets enterotoxigenic E. coli (ETEC) [8][9] - IMM-529 is being developed as an adjunctive therapy for the prevention and treatment of recurrent Clostridioides difficile infection (CDI) [12] - The unique three-target approach of IMM-529 has shown promising results in pre-clinical models, including prevention of primary disease (80% efficacy), protection against disease recurrence (67% efficacy), and treatment of primary disease (78.6% efficacy) [14]

Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [2] - The company is listed on both the Australian Securities Exchange (ASX: IMC) and NASDAQ (NASDAQ: IMRN) [2] Product Information - Travelan® is an orally administered passive immunotherapy that reduces the likelihood of contracting travelers' diarrhea, which is caused by pathogenic bacteria [3] - Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies that binds to diarrhea-causing bacteria, preventing colonization [3] - In Australia, Travelan® is a listed medicine indicated for reducing the risk of travelers' diarrhea and minor gastrointestinal disorders [3] - In Canada, it is a licensed natural health product, while in the U.S., it is sold as a dietary supplement for digestive tract protection [3] Technology and Development - Immuron's proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum, allowing for the production of highly specific immunoglobulins to any enteric pathogen [5] - The platform technology enables the development of medicines across a wide range of infectious diseases, effectively blocking viruses or bacteria at mucosal surfaces [5] Clinical Development - IMM-124E, developed using Immuron's platform technology, targets enterotoxigenic Escherichia coli (ETEC) and is produced from the colostrum of immunized cattle [6][8] - IMM-529 is being developed as an adjunctive therapy for the prevention and treatment of recurrent Clostridioides difficile infection (CDI), targeting key virulence components [9][10] - Pre-clinical results for IMM-529 show promising outcomes in preventing primary disease (80% efficacy), protecting against disease recurrence (67% efficacy), and treating primary disease (78.6% efficacy) [11]

Sales Performance - Immuron Limited reported strong sales growth for Travelan®, with total sales of AUD $1.5 million in the September 2024 Quarter, representing a 13% increase compared to the prior quarter [1] - Sales in Australia increased by 3% to AUD $1.007 million in the September 2024 Quarter, up from AUD $0.983 million in the June 2024 Quarter [2] - North American sales saw a significant increase of 48%, reaching AUD $0.456 million in the September 2024 Quarter compared to AUD $0.309 million in the June 2024 Quarter [3] Market Expansion - The company has secured core ranging in nine additional pharmacy banner groups in Australia, enhancing its market presence [2] - Immuron achieved its strongest monthly sales on amazon.com in the US, indicating robust demand in the North American market [2] - Distribution has expanded to ten pharmacy and grocery retailers in Canada, further solidifying the company's footprint in North America [2] Product Overview - Travelan® is an orally administered passive immunotherapy designed to reduce the likelihood of travelers' diarrhea, which is commonly caused by pathogenic bacteria [3] - The product is a purified tablet preparation of hyper-immune bovine antibodies, which bind to diarrhea-causing bacteria and prevent their colonization [3] - Travelan® is registered as a medicine in Australia and as a licensed natural health product in Canada, while in the U.S., it is marketed as a dietary supplement [3]

Core Viewpoint - Immuron Limited has announced the completion of an interim analysis for a clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) in collaboration with the US Naval Medical Research Command (NMRC) [1][2] Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [14] - The company has developed two commercially available oral immunotherapeutic products for gut-mediated diseases [1] Clinical Trial Details - The NMRC funded the clinical trial, which involved a hyperimmune bovine colostrum product developed by Immuron using a conjugated vaccine targeting Campylobacter and ETEC [3][4] - The trial enrolled 27 volunteers in a randomized, placebo-controlled study, demonstrating a 10.4% protective efficacy against moderate to severe campylobacteriosis compared to the placebo group [5] Future Plans - Immuron plans to hold an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to initiate Phase 3 clinical trials of Travelan® in the second half of 2025 [2] - The company anticipates topline results from a clinical study of Travelan® involving 866 participants, with 85% recruitment completed and results expected in April 2025 [2] Product Information - Travelan® is an orally administered passive immunotherapy that reduces the likelihood of contracting traveler's diarrhea, caused by pathogenic bacteria [12] - The product is available in Australia as a listed medicine and in Canada as a licensed natural health product, while in the U.S., it is sold as a dietary supplement for digestive tract protection [12] Industry Context - Infectious diarrhea is a common illness among travelers and military personnel, with a high priority for preventative treatments due to increasing antibiotic resistance among enteric pathogens [10] - The NMRC is developing new vaccines targeting Campylobacter and ETEC, as well as other pathogens, in collaboration with Immuron [8]

Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Traveler's Diarrhea - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Traveler's Diarrhea - Pipeline Insight, 2024" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Traveler's Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administr ...

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for 1H 2025 MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is p ...